- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01184664
Combination of Nicotine Replacement Therapy (NRT) and Varenicline to Increase Cessation of Tobacco (CONVICT Study) (CONVICT)
October 10, 2012 updated by: Professor Peter Hajek, Queen Mary University of London
Effects of a Combination of Varenicline and Transdermal Nicotine Patch on Post-quitting Urges to Smoke
Varenicline and nicotine replacement therapy (NRT) are both effective smoking cessation treatments.
Anecdotally smokers who are finding their quit attempt difficult have reported benefiting from adding NRT to varenicline.
This proof-of-principle placebo-controlled double-blind study will examine whether combining NRT and varenicline provides better withdrawal and craving relief than varenicline alone.
A total of 120 smokers would be randomised to receive varenicline +15mg/16hr patch or varenicline + placebo patch.
All participants will receive standard NHS Stop Smoking Service support.
The primary outcome would be ratings of craving and withdrawal discomfort 24 hours and one week after the target quit date.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
117
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, E1 2JH
- Tobacco Dependence Research Unit
-
London, United Kingdom, E1 2JH
- Tobacco Dependence Research and Treatment Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Smokers seeking treatment
- Aged 18 and over
- Consenting to take part in the trial
Exclusion Criteria:
- Pregnant or breastfeeding
- End-stage renal disease
- Unable to fill in questionnaires in English
- Previous allergy to Varenicline
- Previous allergy to Nicotine Patches Previous allergy to varenicline
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Varenicline + Active Patch
Participants will use varenicline (1mg BD) + an active, 15mg/16hr Nicotine Patch
|
Varenicline + nicotine patch
Other Names:
All participants will receive a standard dose of varenicline (12 weeks).
Other Names:
|
Placebo Comparator: Varenicline + Placebo Patch
Participants will use varenicline (1mg BD) + a Placebo Nicotine Patch
|
All participants will receive a standard dose of varenicline (12 weeks).
Other Names:
Varenicline + placebo patch
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rating of urges to smoke one week after the target quit date assessed by Mood and Physical Symptoms Scale
Time Frame: 1 week
|
Rating of urges to smoke will be assessed using the Mood and Physical Symptoms Scale
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Validated abstinence rates over weeks 1-12 post target quit date
Time Frame: 12 weeks post target quit date
|
12 weeks post target quit date
|
|
Rating of withdrawal symptoms up to 4-weeks post quitting assessed by Mood and Physical Symptoms Scale
Time Frame: 4-weeks post quitting
|
4-weeks post quitting
|
|
Profile of all adverse effects reported up to 12-weeks post quitting
Time Frame: Up to 12-weeks post quitting
|
Up to 12-weeks post quitting
|
|
Ratings of urges to smoke 24 hours after the target quit date
Time Frame: 24 hours
|
Urges to smoke at 24 hours after the target quit date will be assessed using the Mood & Physical Symptoms Scale
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Al-Rehan A A Dhanji, MB BS BSc MRCS, Queen Mary University of London
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (Actual)
October 1, 2011
Study Completion (Actual)
October 1, 2011
Study Registration Dates
First Submitted
August 17, 2010
First Submitted That Met QC Criteria
August 18, 2010
First Posted (Estimate)
August 19, 2010
Study Record Updates
Last Update Posted (Estimate)
October 11, 2012
Last Update Submitted That Met QC Criteria
October 10, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
- Varenicline
Other Study ID Numbers
- qmul250510
- 2010-022334-92 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on Nicotine Patch
-
McNeil ABCompleted
-
Vanderbilt University Medical CenterCompletedDown Syndrome | Mild Cognitive ImpairmentUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedTobacco Use DisorderUnited States
-
National Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Tobacco Use Disorder | Schizophrenia and Disorders With Psychotic FeaturesUnited States
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedNicotine DependenceUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedBreast Cancer | Colorectal Cancer | Tobacco Use Disorder | Lung Cancer | Prostate CancerUnited States
-
McNeil ABCompleted
-
Massachusetts General HospitalStanley Medical Research Institute; North Suffolk Mental Health AssociationCompleted